JP2016500691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500691A5 JP2016500691A5 JP2015538147A JP2015538147A JP2016500691A5 JP 2016500691 A5 JP2016500691 A5 JP 2016500691A5 JP 2015538147 A JP2015538147 A JP 2015538147A JP 2015538147 A JP2015538147 A JP 2015538147A JP 2016500691 A5 JP2016500691 A5 JP 2016500691A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- nhnr
- heterocycloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 95
- 125000000753 cycloalkyl group Chemical group 0.000 claims 94
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 94
- 125000001072 heteroaryl group Chemical group 0.000 claims 92
- 125000000217 alkyl group Chemical group 0.000 claims 83
- 125000004404 heteroalkyl group Chemical group 0.000 claims 81
- 229910052739 hydrogen Inorganic materials 0.000 claims 78
- 150000002431 hydrogen Chemical class 0.000 claims 78
- 239000001257 hydrogen Substances 0.000 claims 78
- 229910052736 halogen Inorganic materials 0.000 claims 61
- 150000002367 halogens Chemical class 0.000 claims 61
- 150000001875 compounds Chemical class 0.000 claims 28
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 230000001548 androgenic effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 *C(C(N1C2C(*)(*)C(*)(*)C1c1c(*)c(*)c(*C(*)(*)*3)c3c1*)=O)N(*)C2=O Chemical compound *C(C(N1C2C(*)(*)C(*)(*)C1c1c(*)c(*)c(*C(*)(*)*3)c3c1*)=O)N(*)C2=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716803P | 2012-10-22 | 2012-10-22 | |
| US61/716,803 | 2012-10-22 | ||
| US201361799160P | 2013-03-15 | 2013-03-15 | |
| US61/799,160 | 2013-03-15 | ||
| PCT/US2013/066252 WO2014066435A1 (en) | 2012-10-22 | 2013-10-22 | Etp derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000449A Division JP2019070010A (ja) | 2012-10-22 | 2019-01-07 | Ｅｔｐ誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500691A JP2016500691A (ja) | 2016-01-14 |
| JP2016500691A5 true JP2016500691A5 (https=) | 2016-12-15 |
| JP6465803B2 JP6465803B2 (ja) | 2019-02-06 |
Family
ID=50545193
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015538147A Active JP6465803B2 (ja) | 2012-10-22 | 2013-10-22 | Ｅｔｐ誘導体 |
| JP2019000449A Pending JP2019070010A (ja) | 2012-10-22 | 2019-01-07 | Ｅｔｐ誘導体 |
| JP2020079037A Pending JP2020125342A (ja) | 2012-10-22 | 2020-04-28 | Ｅｔｐ誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000449A Pending JP2019070010A (ja) | 2012-10-22 | 2019-01-07 | Ｅｔｐ誘導体 |
| JP2020079037A Pending JP2020125342A (ja) | 2012-10-22 | 2020-04-28 | Ｅｔｐ誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9527868B2 (https=) |
| EP (1) | EP2909214B1 (https=) |
| JP (3) | JP6465803B2 (https=) |
| CN (2) | CN108440571B (https=) |
| AU (1) | AU2013334707B2 (https=) |
| CA (1) | CA2900335C (https=) |
| WO (1) | WO2014066435A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| CN108440571B (zh) * | 2012-10-22 | 2022-11-04 | 希望之城 | Etp衍生物 |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| CN110627770A (zh) | 2013-11-18 | 2019-12-31 | 福马疗法公司 | 作为bet溴域抑制剂的四氢喹啉组成物 |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| PT3077397T (pt) | 2013-12-06 | 2020-01-22 | Vertex Pharma | Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo |
| MX373102B (es) | 2014-06-05 | 2020-04-17 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| EP3733188B1 (en) * | 2015-06-08 | 2023-01-25 | The Regents of the University of California | Use of h3k9me3 modulation for enhancing cognitive function |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| CN109952104B (zh) * | 2016-09-15 | 2023-03-28 | 希望之城 | 二硫etp衍生物 |
| JP7140781B2 (ja) | 2017-05-17 | 2022-09-21 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
| US11766442B2 (en) | 2017-06-16 | 2023-09-26 | City Of Hope | T-cell lymphoma treatments |
| BR112019027133B8 (pt) | 2017-06-20 | 2022-08-09 | Inst Curie | Uso de uma célula imune modificada deficiente para suv39h1 |
| JP2020524157A (ja) | 2017-06-20 | 2020-08-13 | アンスティテュート キュリー | がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤 |
| HRP20240793T1 (hr) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba |
| EP3797108B1 (en) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| LT4003532T (lt) | 2019-07-24 | 2024-11-11 | Constellation Pharmaceuticals, Inc. | 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos |
| CN111205308B (zh) * | 2020-01-19 | 2022-03-15 | 中国科学院海洋研究所 | 一种硫代二酮哌嗪类化合物及其制备方法和应用 |
| EP4188395A1 (en) | 2020-07-30 | 2023-06-07 | Institut Curie | Immune cells defective for socs1 |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| CN114751919B (zh) * | 2022-03-18 | 2023-05-23 | 华南理工大学 | 一种环丁烷稠合螺环吲哚啉类化合物及其制备方法和应用 |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| JP2026501985A (ja) * | 2022-12-20 | 2026-01-20 | シーダーズ―シナイ メディカル センター | パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、および学習障害の処置のための方法および組成物 |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1A (en) * | 1836-07-13 | John Ruggles | Locomotive steam-engine for rail and other roads | |
| DE2157783A1 (de) * | 1971-11-22 | 1973-05-30 | Licentia Gmbh | Verfahren zur korrektur von daten |
| AR206504A1 (es) * | 1972-11-03 | 1976-07-30 | Lepetit Spa | Un procedimiento para preparar 6,7,8,8a-tetrahidro-pirrol(1,2-a)pirazina-1(2h),4(3h)-dionas |
| NZ212051A (en) * | 1984-05-18 | 1988-10-28 | Univ Australian | Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JP2801491B2 (ja) * | 1993-01-26 | 1998-09-21 | 敦 沼田 | エピポリチオジオキソピペラジン誘導体およびその製造法 |
| AU3232597A (en) * | 1996-06-18 | 1998-01-07 | Warner-Lambert Company | Pyrrolo{1,2-a}pyrazine-1,4-dione serine protease inhibitors |
| EP0926242A1 (en) * | 1996-12-02 | 1999-06-30 | Ajinomoto Co., Inc. | Gliotoxin derivatives and anticancer agent comprising the same |
| US7202279B1 (en) * | 1998-02-11 | 2007-04-10 | Georgetown University | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders |
| US6906060B2 (en) * | 2002-06-06 | 2005-06-14 | Novo Nordisk A/S | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines |
| JP4842817B2 (ja) * | 2003-09-03 | 2011-12-21 | ニューレン ファーマシューティカルズ リミテッド | 神経保護二環式化合物およびその使用方法 |
| WO2005110982A2 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
| TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
| ITMI20042477A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche |
| CA2596480A1 (en) * | 2005-02-04 | 2006-08-10 | Wisconsin Alumni Research Foundation | Compounds and methods for modulating communication and virulence in quorum sensing bacteria |
| TW200800204A (en) | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Bicyclic piperazines as metabotropic glutatmate receptor antagonists |
| RU2318818C1 (ru) * | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| WO2008112014A1 (en) * | 2006-10-05 | 2008-09-18 | Mayo Foundation For Medical Education And Research | Methods and compositions for treating cancer |
| EP2088205A1 (en) * | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
| US20120040916A1 (en) * | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| CN103189063B (zh) * | 2010-11-01 | 2016-10-19 | 宾夕法尼亚州研究基金会 | 治疗组合物和方法 |
| CN108440571B (zh) * | 2012-10-22 | 2022-11-04 | 希望之城 | Etp衍生物 |
| CN105229013B (zh) * | 2013-05-24 | 2018-09-14 | 梨花女子大学校产学协力团 | 桥二硫双氧代哌嗪化合物或它的衍生物，及其用途 |
-
2013
- 2013-10-22 CN CN201810252982.1A patent/CN108440571B/zh active Active
- 2013-10-22 EP EP13849813.4A patent/EP2909214B1/en active Active
- 2013-10-22 WO PCT/US2013/066252 patent/WO2014066435A1/en not_active Ceased
- 2013-10-22 AU AU2013334707A patent/AU2013334707B2/en active Active
- 2013-10-22 CA CA2900335A patent/CA2900335C/en active Active
- 2013-10-22 CN CN201380065997.2A patent/CN104870452B/zh active Active
- 2013-10-22 JP JP2015538147A patent/JP6465803B2/ja active Active
-
2015
- 2015-04-17 US US14/689,682 patent/US9527868B2/en active Active
-
2016
- 2016-08-19 US US15/242,318 patent/US9856273B2/en active Active
-
2017
- 2017-10-27 US US15/796,363 patent/US10246471B2/en active Active
-
2019
- 2019-01-07 JP JP2019000449A patent/JP2019070010A/ja active Pending
-
2020
- 2020-04-28 JP JP2020079037A patent/JP2020125342A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500691A5 (https=) | ||
| JP2014518286A5 (https=) | ||
| RU2015126795A (ru) | Минующие нуклеозид киназу композиции и способы их получения и применения | |
| DOP2019000022A (es) | Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
| DOP2011000367A (es) | DERIVADOS DE SULFONAMIDA SUSTITUIDA CON 1H-PIRROLO[2,3,b]PIRIDIN-5-ILOXI COMO AGENTES INDUCTORES DE APOPTOSIS PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES Y AUTOINMUNES | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| HRP20200521T1 (hr) | Kombinacijske terapije za liječenje kemorezistentnih rakova | |
| JP2019518766A5 (https=) | ||
| JP2021517116A5 (https=) | ||
| CO6640275A2 (es) | Agentes indictores de apotosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes | |
| RU2015126856A (ru) | Дисульфидные маскированные пролекарственные композиции и способы | |
| TN2016000503A1 (en) | Pyrazolopyridines and pyrazolopyrimidines | |
| JP2015522650A5 (https=) | ||
| JP2013522292A5 (https=) | ||
| JP2013541586A5 (https=) | ||
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| JP2008505167A5 (https=) | ||
| JP2016501838A5 (https=) | ||
| JP2016503300A5 (https=) | ||
| NI201500049A (es) | Análogos de 2' - cloro nucleósido para infecciones por vhc | |
| JP2017524013A5 (https=) | ||
| WO2015081133A3 (en) | Nucleotides for the treatment of liver cancer | |
| JP2014508753A5 (https=) | ||
| JP2013521291A5 (https=) | ||
| JP2013502441A5 (https=) |